What Is Platelet-Rich Fibrin (PRF) and How Does It Work?

Platelet-rich fibrin is a healing material made entirely from your own blood, designed to concentrate the cells and signaling molecules that drive tissue repair into a single, usable clot or membrane. A small blood draw is spun in a centrifuge, and within minutes the result is a dense fibrin matrix loaded with platelets, white blood cells, and growth factors that can be placed into a surgical site, injected under skin, or layered over a wound. Unlike its predecessor, platelet-rich plasma, PRF requires no chemical additives, which has made it attractive across dentistry, dermatology, wound care, and orthopedics. The science behind it is more nuanced than the marketing often suggests, though, and the clinical evidence varies depending on where and how it is used.

How PRF Is Made

The preparation is surprisingly low-tech. A clinician draws a small volume of venous blood, typically around 10 milliliters split between two tubes, and immediately places those tubes in a tabletop centrifuge. Speed and timing matter, but the general idea is simple: spinning separates the blood by density. Red blood cells, the heaviest component, sink to the bottom. A pale yellow layer of platelet-poor plasma rises to the top. In between sits the PRF clot itself, a golden-to-amber layer rich in fibrin, platelets, and white blood cells.¹

The critical detail is that no anticoagulant or activating chemical is added to the tubes. The blood begins clotting naturally as soon as it contacts the tube walls, and the centrifuge organizes the clot into layers before it fully solidifies. This natural polymerization is what gives PRF its characteristic structure: a fibrin scaffold that traps cells in a three-dimensional network rather than simply suspending them in liquid.² The whole process takes about eight to twelve minutes from blood draw to finished product, and because it uses only the patient’s own blood, there is essentially no risk of immune rejection or disease transmission.

What Is Actually Inside a PRF Membrane

A well-prepared PRF clot captures roughly 97% of the platelets and more than half of the white blood cells from the original blood sample.³ Those cells are not scattered evenly throughout. Platelets and large fibrin clusters concentrate near the red-blood-cell boundary at the bottom of the clot, while the upper portion has a looser, more porous structure. The porosity of the fibrin network increases gradually from about 6% near the red-cell end to around 40% at the plasma end.⁴ This gradient matters clinically: the denser bottom portion is where most of the platelets and leukocytes cluster, making that zone the most biologically active part of the membrane.

The white blood cells trapped in PRF are not there by accident. Leukocytes play a direct role in wound healing by releasing immune-regulating cytokines and helping to coordinate the early inflammatory response at a surgical or wound site.⁵ The monocytes within the clot can differentiate into macrophages over the course of about a week, further amplifying the repair process.⁶ Compared to a related product called platelet-rich fibrin matrix, standard PRF traps a greater number of both platelets and leukocytes, which appears to contribute to stronger antimicrobial properties.⁷

How PRF Differs from PRP

Platelet-rich plasma, or PRP, is the older technology. It requires two rounds of centrifugation and the addition of an anticoagulant to keep the blood liquid, followed by an activator to trigger clotting at the point of use. Those extra chemicals can interfere with the body’s natural healing cascade and add cost and complexity.⁸ PRF was developed specifically to eliminate those steps: one centrifugation, no additives, a simpler and cheaper workflow.

The biological differences go beyond convenience. Proteomic analysis has identified nearly 400 distinct proteins in these concentrates, and PRF tends to contain a higher concentration of leukocytes than PRP. In laboratory models, PRF induced significantly more new blood vessel formation and branching compared to PRP, suggesting stronger pro-angiogenic potential. The presence of those extra leukocytes also appeared to steer macrophages toward an anti-inflammatory state rather than a pro-inflammatory one.⁹ In skin fibroblast cultures, a liquid form of PRF drove significantly higher collagen synthesis and cell migration than PRP did.¹⁰

The Growth Factor Release Pattern

One of PRF’s key selling points is that it does not dump all its growth factors at once. Because the cells are physically trapped inside a fibrin scaffold, the signaling molecules are released gradually as the fibrin breaks down. In lab studies, both solid and liquid forms of PRF continued releasing growth factors for about ten days, with a peak around day seven before tapering off.¹¹ This slow-release behavior is thought to better mimic the body’s natural wound healing timeline compared to PRP, which delivers a larger initial burst that fades more quickly.

The growth factors involved are the usual players in tissue repair. PDGF helps recruit cells to the wound site and stimulates their division. TGF-beta promotes collagen production and tissue remodeling. VEGF, or vascular endothelial growth factor, drives the formation of new blood vessels, a process essential for delivering oxygen and nutrients to healing tissue. EGF stimulates surface cell growth. These are all naturally present in your blood; PRF simply concentrates them and delivers them where they are needed.

How PRF Drives Tissue Repair

The repair process works on several fronts simultaneously. In terms of blood vessel formation, lab studies have shown that substances released from PRF significantly increase endothelial cell activity, including their metabolic rate, their ability to migrate, and their capacity to form tube-like structures that become new capillaries.¹² This angiogenic effect has also been demonstrated with stem cells from fat tissue in a diabetic wound model, where PRF promoted endothelial cell differentiation and new vessel formation.¹³

On the structural side, PRF boosts collagen production. A systematic review of lab studies found that PRF increased type 1 collagen expression in cells from bone, skin, and gum tissue.¹⁴ Collagen is the primary structural protein in connective tissue, so ramping up its production is directly relevant to rebuilding skin, gums, and bone.

PRF also has some antibacterial activity. Lab testing has shown that both standard and horizontally centrifuged PRF clots reduce colony counts of common bacteria like Staphylococcus aureus and E. coli.¹⁵ Against oral pathogens specifically, PRF membranes showed clear inhibition of Porphyromonas gingivalis, a major player in gum disease, though the effect was not universal across all tested bacterial species.¹⁶ This is not a replacement for antibiotics, but it does offer a modest extra layer of protection at a wound site.

Where Dentists Use PRF

Dentistry is where PRF has the longest track record and the broadest range of applications. After a tooth extraction, the empty socket naturally loses some bone volume as it heals, a process called ridge resorption. Clinicians place PRF membranes into extraction sockets to help preserve the bone ridge for future implants. One clinical trial found that PRF performed about as well as freeze-dried bone allograft in preserving ridge height, with no statistically significant difference between the two groups.¹⁷ That said, new bone formation ratios in PRF-treated sockets were only modestly higher than in untreated control sockets, and the difference did not reach statistical significance in at least one randomized trial.¹⁸

Another common dental application is treating gum recession. A meta-analysis comparing PRF membranes to connective tissue grafts (the traditional approach, where a strip of tissue is harvested from the roof of the mouth) found no significant difference between the two in probing depth, attachment level, or recession coverage.¹⁹ A more recent systematic review of an advanced form of PRF confirmed similar findings: connective tissue grafts still showed a somewhat greater reduction in recession depth, but the differences in most other measures were not clinically meaningful.²⁰ The practical appeal is that PRF eliminates the second surgical site at the palate, which means less pain and faster recovery for the patient. That trade-off makes it a reasonable option for mild to moderate recession even if connective tissue grafts maintain a slight edge in outcomes.

Skin Rejuvenation and Hair Loss

Injectable PRF has become a buzzword in aesthetics, marketed as a natural alternative to hyaluronic acid fillers and a next-generation version of the “vampire facial.” The evidence, while still limited in scale, is encouraging. In one prospective study of injectable PRF for facial rejuvenation, participants showed significant improvements in skin spots and pore appearance at three months, along with high satisfaction scores across multiple facial zones.²¹ For periorbital wrinkles specifically, a clinical trial observed noticeable improvement in both deep and fine wrinkles, with swelling limited to about one day after injection.²² PRF gel has also been introduced as an autologous option for under-eye hollowing, aimed at patients who want a more conservative approach than synthetic fillers.²³

For hair loss, particularly androgenetic alopecia (the common pattern hair loss affecting both men and women), injectable PRF is showing real promise. A systematic review found that PRF demonstrated the fastest and most consistent responses among regenerative therapies studied, with improvements in hair density ranging from about 62% to 97% within three to six months.²⁴ A study focused specifically on injectable PRF for this condition reported an 80% response rate at six months, with significant improvements in hair density, reduced scalp inflammation, and high patient satisfaction scores, alongside minimal side effects.²⁵ These numbers are impressive, though the field still needs larger, longer-term trials with control groups to nail down exactly how much better PRF performs compared to PRP or placebo.

Wound Healing

Chronic wounds, such as diabetic ulcers and venous leg ulcers, are notoriously difficult to heal. PRF is being studied as an adjunct to standard wound care in these cases. A retrospective study comparing PRF-treated chronic wounds to conventionally treated ones found that wounds in the PRF group healed in about 36 days on average versus 60 days in the control group.²⁶ A separate case series using various platelet concentrates, including PRF membranes and injectable PRF, reported complete wound closure in just under half of cases and an average surface area improvement of 50%.²⁷

These results are meaningful but need context. Retrospective studies and case series sit near the bottom of the evidence hierarchy. The patients who received PRF may have differed from controls in ways that influenced healing. Randomized trials are still catching up, and the wound-care community is waiting for larger, better-controlled studies before declaring PRF a standard-of-care intervention. Still, the direction of the evidence is consistently positive, and the risk profile is extremely low since you are using your own blood.

Orthopedics and Sports Medicine

Research generally supports using PRF as an add-on treatment for chronic musculoskeletal injuries, including cartilage damage, rotator cuff repairs, and anterior cruciate ligament reconstruction.²⁸ The catch is that the evidence base is fragmented. Different studies use different preparation protocols, different doses, and different ways of applying the material, which makes it hard to draw firm conclusions about how much benefit PRF actually adds to a given surgical procedure.²⁹ The enthusiasm in sports medicine clinics has outpaced the data somewhat, and patients considering PRF for a knee or shoulder injury should know they are opting for a biologically plausible but not yet robustly proven therapy.

Why Centrifuge Settings and Tube Choice Matter More Than You Would Think

PRF is often presented as a simple, standardized product, but the reality is that small changes in how it is made can significantly alter what you end up with. A study evaluating 24 different centrifuge protocols found that the optimal settings for solid PRF fell in a relatively narrow window, roughly 400 to 700 g of centrifugal force for about eight minutes. Going too fast or too long pushed leukocytes out of the clot, while going too slow failed to separate the layers properly.³⁰ Reducing centrifugal force, a concept sometimes called “low speed centrifugation,” has been shown to yield higher cell counts and greater growth factor release, which has driven newer PRF formulations toward gentler spinning protocols.³¹

Even the collection tubes matter. Research has shown that PRF clots produced in plain glass tubes are roughly twice the size of those produced in silica-coated plastic tubes. Tubes with silicone coatings performed even worse; some samples failed to clot at all after a standard centrifugation cycle.³² Newer additive-free plastic tubes can produce PRF with a higher platelet percentage, though the fibrin network tends to be less dense than what glass tubes yield.³³ These details rarely make it into patient-facing marketing, but they help explain why results can vary between clinics using what they all call “PRF.”

Does Your Age or Sex Change the Result

Your body’s starting blood composition affects what comes out of the centrifuge. One study found that the highest platelet concentration, antimicrobial activity, and fibrin network density were obtained from donors in the 20-to-34-year age range.³⁴ A separate study looking at membrane size found that female patients produced membranes about 17% larger than those from male patients, though membrane size did not differ significantly across age groups.³⁵

The practical implication is real but modest. A younger patient in good health will generally produce a more cell-rich clot than an older patient with underlying metabolic issues. But the differences are gradual, not binary, and older patients still benefit from PRF. Factors beyond age, such as immune status and overall metabolic health, also influence what your blood can deliver.³⁶ The centrifugation protocol matters at least as much as the patient’s demographics, and perhaps more.

Newer PRF Variants

The PRF family has grown since the original solid-clot version was introduced. Injectable PRF (i-PRF) uses lower centrifugal force and shorter spin times to produce a liquid concentrate rather than a solid membrane, making it suitable for injection into skin, scalp, or joint spaces. A further refinement called concentrated PRF (C-PRF) modifies this liquid form to pack in even more cells. Comparing the two, C-PRF released significantly more key growth factors, including PDGF, TGF-beta, and EGF, and induced greater fibroblast migration and collagen production than standard i-PRF.³⁷

Advanced PRF (A-PRF and A-PRF+) uses modified centrifugation to capture even more leukocytes. In one study, A-PRF+ conditioned medium stimulated more mineralization and calcium production in bone-like cells over 28 days compared to controls, suggesting enhanced bone-building potential.³⁸ These newer formulations are not necessarily “better” across the board; each is optimized for a different clinical scenario. A solid membrane makes sense for packing into a tooth socket, while a liquid injectable is more appropriate for scalp injections or joint spaces. The proliferation of variants makes it important to know which version your provider is using and why.

Regulation and What to Ask Your Provider

PRF occupies a regulatory gray area in many countries. Because it is made from your own blood at the point of care, it often falls outside the rules that govern manufactured drugs or medical devices. Japan is the notable exception, having established what is considered the strictest regulatory framework for platelet concentrate therapies in the world. Under Japan’s 2014 Act on the Safety of Regenerative Medicine, platelet concentrates prepared for clinical use must meet standards comparable to those applied to stem cell products, including formal standard operating procedures.³⁹ Most other countries have no equivalent oversight, meaning the quality of PRF you receive depends heavily on your provider’s equipment, training, and attention to preparation details.

Given the technical sensitivity discussed earlier, a few questions are worth asking before a PRF procedure. What type of collection tubes are being used, and are they free of silica and silicone coatings? What centrifugation protocol is being followed, and is it aligned with current research? Is the blood drawn and spun immediately, or does it sit before processing? That last point matters because a delay between the blood draw and centrifugation gives the clot time to form prematurely in the tube, potentially reducing the quality of the final product. None of these questions have answers that a typical patient would be expected to evaluate independently, but a provider who is well-versed in the science should be able to answer them comfortably. That comfort level tells you something about whether the clinic has kept up with the rapidly evolving literature or is simply following a recipe from a weekend seminar.